This study reports on the efficacy and safety of low-dose topiramate
in the treatment of children with chronic daily headache. Topiramate
is one of the new antiepileptic drugs commonly being used for migraine
in adults as well as children and was recently approved by the Food
and Drug Administration for migraine treatment in adults. This report
presents the researchers' experience with low-dose topiramate for the
treatment of chronic daily headache in 21 patients, aged 6 through 18
years. Sixty-two percent of families reported that low-dose topiramate
(average dose of 30 mg/day) was successful in reducing the frequency
and severity headaches. The headache frequency decreased from 22.8 to
7.2 headaches/month and severity decreased from a pain score of 8.1
to 3.7. The researchers conclude that Topiramate was safe, well tolerated,
and highly effective at low doses in the treatment of chronic daily
headaches. Borzy JC, Koch TK, Schimschock JR. Adapted from Pediatr Neurol.
2005 Nov;33(5):314-316.
PMID 16243217
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16243217&query_hl=2
Credit: PubMed, developed by the National Center for Biotechnology Information
(NCBI) at the National
Library of Medicine (NLM).
|